These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7032940)

  • 1. Hydroxy-9-methyl-2-Ellipticinium (NSC 264-137) in 52 cases of osseous metastases from breast cancer.
    Juret P; Le Talaer Y; Couette JE; Delozier T
    Eur J Cancer (1965); 1980; Suppl 1():277-9. PubMed ID: 7032940
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hydroxy-9-methyl-2-ellipticinium (NSC 264-137) for osseous metastases from breast cancer. A 4 year experience (author's transl)].
    Juret P; Couette JE; Delozier T; Le Talaer JY
    Bull Cancer; 1981; 68(3):224-31. PubMed ID: 7039729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.
    Juret P; Heron JF; Couette JE; Delozier T; Le Talaer JY
    Cancer Treat Rep; 1982 Nov; 66(11):1909-16. PubMed ID: 7139636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hydroxy 9-methyl 2-ellipticinium acetate (NSC 264-137). Toxicologic study and therapeutic effect in 100 cancers (author's transl)].
    Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Yuong ; Le Pecq JB; Paoletti C
    Nouv Presse Med; 1979 Apr; 8(18):1495-8. PubMed ID: 471724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal toxicity of 9-hydroxy-2-methyl-ellipticinium].
    Ryckelynck JP; Heron JF; Juret P; Schneider P; Herlin P; De Ranieri E; Hardouin A; Peny J; Le Talaer JY
    Nephrologie; 1984; 5(2):59-63. PubMed ID: 6483073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [2 N methyl 9 hydroxy-ellipticine in treatment of metastatic breast cancers (author's transl)].
    Rouëssé J; Huertas D; Sancho-Garnier H; Le Chevalier T; Amiel JL; Brulé G; Tursz T; Mondésir JM
    Bull Cancer; 1981; 68(5):437-41. PubMed ID: 7037078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)].
    Rouesse J; Tursz T; Le Chevalier T; Huertas D; Amiel JL; Brule G; Callet B; Droz JP; Voisin PM; Sancho-Garnier H; Le Pecq JB; Paoletti C
    Nouv Presse Med; 1981 May; 10(24):1997-9. PubMed ID: 7255136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264--137) in advanced human cancers.
    Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Xuong N; Le Pecq JB; Paoletti C
    Eur J Cancer (1965); 1978 Feb; 14(2):205-6. PubMed ID: 342255
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast.
    Sternberg CN; Yagoda A; Casper E; Scoppetuolo M; Scher HI
    Anticancer Res; 1985; 5(4):415-7. PubMed ID: 4037737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group.
    Anderson G; Clavel M; Smyth J; Giaccone G; Gracia M; Planting AS; Dalesio O; Kirkpatrick A; McVie G
    Eur J Cancer Clin Oncol; 1989 May; 25(5):909-10. PubMed ID: 2737223
    [No Abstract]   [Full Text] [Related]  

  • 11. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
    Paoletti C; Le Pecq JB; Dat-Xuong N; Juret P; Garnier H; Amiel JL; Rouesse J
    Recent Results Cancer Res; 1980; 74():107-23. PubMed ID: 7003658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [2 new antineoplastic derivatives: 9-hydroxy-2-methyl-ellipticinium (acetate) and 9-hydroxy-2,6-dimethyl-ellipticinium (chloride). Effect on mouse L 1210 leukemia].
    Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C
    C R Acad Hebd Seances Acad Sci D; 1975 Nov; 281(18):1365-7. PubMed ID: 815025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in breast cancer patients with skeletal metastases.
    Shapiro CL
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):153-63. PubMed ID: 8150777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
    Horváth Z
    Magy Onkol; 2002; 46(4):361-4. PubMed ID: 12563361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Letter: L. Dopa and bone metastases in breast cancer].
    Ghozian D; Amor B; Delbarre F
    Nouv Presse Med; 1974 Mar; 3(11):678. PubMed ID: 4599794
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Double-blind trial of oral clodronate in breast cancer patients with bone metastases].
    Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
    Bull Cancer; 1993; 80(10 Suppl):50-6. PubMed ID: 8081032
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of bisphosphonates in breast cancer.
    Coleman RE
    Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic value of whole-body MRI and bone scintigraphy in the detection of osseous metastases in patients with breast cancer--A Prospective Double-Blinded Study at two Hospital Centers].
    Ohlmann-Knafo S; Kirschbaum M; Fenzl G; Pickuth D
    Rofo; 2009 Mar; 181(3):255-63. PubMed ID: 19229791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.